101-200

101. 長谷川浩一，沢山俊民，伊吹山千晴，他．急性肺塞栓症の早期診断と治療対策　多施設225例の臨床的解析．呼吸と循環1993; 41: 773-777.

102. Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967; 20: 457-

464.

103. Timmis AD. Early diagnosis of acute myocardial infarction. BMJ 1990; 301: 941-942.

104. Tsukahara K, Kimura K, Kosuge M, et al. Clinical implications of intermediate QRS prolongation in the absence of bundle-branch block in patients with

ST-segment-elevation acute myocardial infarction. Circ J 2005; 69: 29-34.

105. Hirano T, Tsuchiya K, Nishigaki K, et al. Clinical features of emergency electrocardiography in patients with acute myocardial infarction caused by left

main trunk obstruction. Circ J 2006; 70: 525-529.

106. Hochrein J, Sun F, Pieper KS, et al. Higher T-wave amplitude associated with better prognosis in patients receiving thrombolytic therapy for acute

myocardial infarction (a GUSTO-I substudy). Global Utilization of Streptokinase and Tissue plasminogen Activator for Occluded Coronary Arteries. Am

J Cardiol 1998; 81: 1078-1084.

107. Braat SH, Brugada P, de Zwaan C, et al. Value of electrocardiogram in diagnosing right ventricular involvement in patients with an acute inferior wall

myocardial infarction. Br Heart J 1983; 49: 368-372.

108. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all

randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Lancet 1994; 343: 311-322.

109. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial

infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation 1994; 89: 1545-1556.

110. Rude RE, Poole WK, Muller JE, et al. Electrocardiographic and clinical criteria for recognition of acute myocardial infarction based on analysis of

3,697 patients. Am J Cardiol 1983; 52: 936-942.

111. Weaver WD, Eisenberg MS, Martin JS, et al. Myocardial Infarction Triage and Intervention Project―phase I: patient characteristics and feasibility of

prehospital initiation of thrombolytic therapy. J Am Coll Cardiol 1990; 15: 925-931.

112. Karlson BW, Herlitz J, Wiklund O, et al. Early prediction of acute myocardial infarction from clinical history, examination and electrocardiogram in the

emergency room. Am J Cardiol 1991; 68: 171-175.

113. Fisch C. The clinical electrocardiogram: sensitivity and specificity. ACC Curr J Rev 1997; 6: 71-75.

114. Wang K, Asinger RW, Marriott HJ. ST-segment elevation in conditions other than acute myocardial infarction. N Engl J Med 2003; 349: 2128-2135.

115. Sgarbossa EB, Pinski SL, Barbagelata A, et al. Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-

branch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators. N Engl

J Med 1996; 334: 481-487.

116. 有馬健，長尾建，上松瀬勝男，他．左主幹部閉塞を認めた急性心筋梗塞症例の心電図所見と予後．日救急医会誌 1996; 7: 69-75.

117. Yamaji H, Iwasaki K, Kusachi S, et al. Prediction of acute left main coronary artery obstruction by 12-lead electrocardiography. ST segment elevation

in lead aVR with less ST segment elevation in lead V(1). J Am Coll Cardiol 2001; 38: 1348-1354.

118. Kligfield P, Gettes LS, Bailey JJ, et al. Recommendations for the standardization and interpretation of the electrocardiogram: part I: The

electrocardiogram and its technology: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee,

Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society

for Computerized Electrocardiology. Circulation 2007; 115: 1306-1324.

119. Kosuge M, Ebina T, Hibi K, et al. Simple and accurate electrocardiographic criteria to differentiate takotsubo cardiomyopathy from anterior acute

myocardial infarction. J Am Coll Cardiol 2010; 55: 2514-2516.

120. Field JM, Hazinski MF, Sayre MR, et al. Part 1: executive summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation

and Emergency Cardiovascular Care. Circulation 2010; 122: S640-656.

121. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the

Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29:

2909-2945.

122. Adams GL, Campbell PT, Adams JM, et al. Effectiveness of prehospital wireless transmission of electrocardiograms to a cardiologist via hand-held

device for patients with acute myocardial infarction (from the Timely Intervention in Myocardial Emergency, NorthEast Experience [TIME-NE]). Am J

Cardiol 2006; 98: 1160-1164.

123. Afolabi BA, Novaro GM, Pinski SL, et al. Use of the prehospital ECG improves door-to-balloon times in ST segment elevation myocardial infarction

irrespective of time of day or day of week. Emerg Med J 2007; 24: 588-591.

124. Terkelsen CJ, Lassen JF, Norgaard BL, et al. Reduction of treatment delay in patients with ST-elevation myocardial infarction: impact of pre-hospital

diagnosis and direct referral to primary percutanous coronary intervention. Eur Heart J 2005; 26: 770-777.

125. Dhruva VN, Abdelhadi SI, Anis A, et al. ST-Segment Analysis Using Wireless Technology in Acute Myocardial Infarction (STAT-MI) trial. J Am Coll

Cardiol 2007; 50: 509-513.

126. Sekulic M, Hassunizadeh B, McGraw S, et al. Feasibility of early emergency room notification to improve door-to-balloon times for patients with

acute ST segment elevation myocardial infarction. Catheter Cardiovasc Interv 2005; 66: 316-319.

127. Kojima S, Sakamoto T, Ishihara M, et al. Japanese Acute Coronary Syndrome Study investigators. The white blood cell count is an independent

predictor of no-reflow and mortality following acute myocardial infarction in the coronary interventional era. Ann Med 2004; 36: 153-160.

128. Wahab NN, Cowden EA, Pearce NJ, et al. ICONS Investigators. Is blood glucose an independent predictor of mortality in acute myocardial infarction

in the thrombolytic era? J Am Coll Cardiol 2002; 40: 1748-1754.

129. Iwakura K, Ito H, Ikushima M, et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction.

J Am Coll Cardiol 2003; 41: 1-7.

130. Kosuge M, Kimura K, Kojima S, et al; Japanese Acute Coronary Syndrome Study (JACSS) Investigators. Effects of glucose abnormalities on in-

hospital outcome after coronary intervention for acute myocardial infarction. Circ J 2005; 69: 375-379.

131. Luepker RV, Apple FS, Christenson RH, et al. Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a

statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology

and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention;

and the National Heart, Lung, and Blood Institute. Circulation 2003; 108: 2543-2549.

132. Katus HA, Remppis A, Looser S, et al. Enzyme linked immuno assay of cardiac troponin T for the detection of acute myocardial infarction in

patients. J Mol Cell Cardiol 1989; 21: 1349-1353.

133. Ahumada G, Roberts R, Sobel BE. Evaluation of myocardial infarction with enzymatic indices. Prog Cardiovasc Dis 1976; 18: 405-420.

134. Lee TH, Goldman L. Serum enzyme assays in the diagnosis of acute myocardial infarction. Recommendations based on a quantitative analysis.

Ann Intern Med 1986; 105: 221-233.

135. Halkin A, Stone GW, Grines CL, et al. Prognostic implications of creatine kinase elevation after primary percutaneous coronary intervention for acute

myocardial infarction. J Am Coll Cardiol 2006; 47: 951-961.

136. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Circulation 2007; 116: 2634-2653.

137. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation 2012; 126: 2020-2035.

138. Tanaka K, Seino Y, Ohbayashi K, et al. Cardiac emergency triage and therapeutic decisions using whole blood rapid troponin T test for patients with

suspicious acute coronary syndrome. Jpn Circ J 2001; 65: 424-428.

139. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009;

361: 858-867.

140. Keller T, Zeller T, Peetz D, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 2009; 361: 868-877.

141. Seino Y, Ogata K, Takano T, et al. Use of a whole blood rapid panel test for heart-type fatty acid-binding protein in patients with acute chest pain:

comparison with rapid troponin T and myoglobin tests. Am J Med 2003; 115: 185-190.

142. 日本版救急蘇生ガイドライン策定小委員会．救急蘇生法の指針2005─医療従事者用（改訂3版）．へるす出版 2007.

143. Kontos MC, Arrowood JA, Paulsen WH, et al. Early echocardiography can predict cardiac events in emergency department patients with chest pain.

Ann Emerg Med 1998; 31: 550-557.

144. Autore C, Agati L, Piccininno M, et al. Role of echocardiography in acute chest pain syndrome. Am J Cardiol 2000; 86: 41G-42G.

145. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an

international trial of 41,021 patients. GUSTO-I Investigators. Circulation 1995; 91: 1659-1668.

146. Mehilli J, Kastrati A, Dirschinger J, et al. Sex-based analysis of outcome in patients with acute myocardial infarction treated predominantly with

percutaneous coronary intervention. JAMA 2002; 287: 210-215.

147. Kosuge M, Kimura K, Kojima S, et al. Japanese Acute Coronary Syndrome Study (JACSS) Investigators. Sex differences in early mortality of patients

undergoing primary stenting for acute myocardial infarction. Circ J 2006; 70: 217-221.

148. Mehta RH, O’neill WW, Harjai KJ, et al. Primary Angioplasty in Myocardial Infarction (PAMI) and the Controlled Abciximab and Device Investigation to

Lower Late Angioplasty Complications (CADILLAC) Investigators. Prediction of one-year mortality among 30-day survivors after primary percutaneous

coronary interventions. Am J Cardiol 2006; 97: 817-822.

149. Jeger RV, Harkness SM, Ramanathan K, et al. Emergency revascularization in patients with cardiogenic shock on admission: a report from the

SHOCK trial and registry. Eur Heart J 2006; 27: 664-670.

150. Hochman JS, Sleeper LA, White HD, et al; SHOCK Investigators. One-year survival following early revascularization for cardiogenic shock. JAMA

2001; 285: 190-192.

151a. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK

Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 1999; 341: 625-634.

151b. Webb JG, Sleeper LA, Buller CE, et al. Implications of the timing of onset of cardiogenic shock after acute myocardial infarction: a report from the

SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol 2000; 36: 1084-1090.

152. Fox KA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary

syndrome: prospective multinational observational study (GRACE). BMJ 2006; 333: 1091.

153. Eagle KA, Lim MJ, Dabbous OH, et al. GRACE Investigators. A validated prediction model for all forms of acute coronary syndrome: estimating the

risk of 6-month postdischarge death in an international registry. JAMA 2004; 291: 2727-2733.

154. Nakatani D, Sakata Y, Suna S, et al. Impact of beta blockade therapy on long-term mortality after ST-segment elevation acute myocardial infarction in

the percutaneous coronary intervention era. Am J Cardiol 2013; 111: 457-464.

155. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk

assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000; 102: 2031-2037.

156. Morrow DA, Antman EM, Giugliano RP, et al. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II

substudy. Lancet 2001; 358: 1571-1575.

157. Halkin A, Singh M, Nikolsky E, et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the

CADILLAC risk score. J Am Coll Cardiol 2005; 45: 1397-1405.

158. Maroko PR, Radvany P, Braunwald E, et al. Reduction of infarct size by oxygen inhalation following acute coronary occlusion. Circulation 1975; 52:

360-368.

159. Fillmore SJ, Shapiro M, Killip T. Arterial oxygen tension in acute myocardial infarction. Serial analysis of clinical state and blood gas changes. Am

Heart J 1970; 79: 620-629.

160. Bussmann WD, Passek D, Seidel W, et al. Reduction of CK and CK-MB indexes of infarct size by intravenous nitroglycerin. Circulation 1981; 63: 615-

622.

161. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial

infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico. Lancet 1994; 343: 1115-1122.

162. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with

suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995; 345: 669-685.

163. Cheitlin MD, Hutter AM Jr, Brindis RG, et al. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease.

American College of Cardiology/American Heart Association.J Am Coll Cardiol 1999; 33: 273-282.

164. Every NR, Parsons LS, Hlatky M, et al. A comparison of thrombolytic therapy with primary coronary angioplasty for acute Intervention Investigators. N

Engl J Med 1996; 335: 1253-1260.

165. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.

ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2: 349-360.

166. Freimark D, Matetzky S, Leor J, et al. Timing of aspirin administration as a determinant of survival of patients with acute myocardial infarction treated

with thrombolysis. Am J Cardiol 2002; 89: 381-385.

167. Barbash I, Freimark D, Gottlieb S, et al. Israeli working group on intensive cardiac care， Israel heart society. Outcome of myocardial infarction in

patients treated with aspirin is enhanced by prehospital administration. Cardiology 2002; 98: 141-147.

168. Fuster V, Dyken ML, Vokonas PS, et al. Aspirin as a therapeutic agent in cardiovascular disease. Special Writing Group. Circulation 1993; 87: 659-

675.

169. Becker RC. Antiplatelet therapy in coronary heart disease. Emerging strategies for the treatment and prevention of acute myocardial infarction. Arch

Pathol Lab Med 1993; 117: 89-96.

170. Juul-Moller S, Edvardsson N, Jahnmatz B, et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable

chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992; 340: 1421-1425.

171. Yasue H, Ogawa H, Tanaka H, et al. Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Japanese Antiplatelets

Myocardial Infarction Study (JAMIS) Investigators. Am J Cardiol 1999; 83: 1308-1313.

172. Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin

compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study

(CLASSICS). Circulation 2000; 102: 624-629.

173. Cadroy Y, Bossavy JP, Thalamas C, et al. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental

arterial thrombogenesis in humans. Circulation 2000; 101: 2823-2828.

174. Muller I, Seyfarth M, Rudiger S, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.

Heart 2001; 85: 92-93.

175. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment

elevation. Eur Heart J 2012; 33: 2569-2619.

176. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-

controlled trial. Lancet 2005; 366: 1607-1621.

177. MacMahon S, Collins R, Knight C, et al. Reduction in major morbidity and mortality by heparin in acute myocardial infarction. Circulation 1988; 78: II-

98.

178. Verheugt FW, Liem A, Zijlstra F, et al. High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: results of

the Heparin in Early Patency (HEAP) pilot study. J Am Coll Cardiol 1998; 31: 289-293.

179. de Bono DP, Simoons ML, Tijssen J, et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after

alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. Br Heart J 1992; 67: 122-128.

180. Bleich SD, Nichols TC, Schumacher RR, et al. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in

acute myocardial infarction. Am J Cardiol 1990; 66: 1412-1417.

181. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993;

329: 673-682.

182. O’Connor CM, Meese R, Carney R, et al. A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen

streptokinase activator complex) in acute myocardial infarction: the Duke University Clinical Cardiology Study (DUCCS) 1. J Am Coll Cardiol 1994; 23:

11-18.

183. Chong BH, Berndt MC. Heparin-induced thrombocytopenia. Blut 1989; 58: 53-57.

184. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996; 101: 502-507.

185. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001; 135: 502-506.

186. Jang IK, Hursting MJ. When heparins promote thrombosis: review of heparin-induced thrombocytopenia. Circulation 2005; 111: 2671-2683.

187. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct

Survival Collaborative Group. Lancet 1986; 2: 57-66.

188. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982; 247: 1707-1714.

189. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction (NMS). N Engl J Med 1981; 304: 801-807.

190. The beta-blocker heart attack trial. beta-Blocker Heart Attack Study Group. JAMA 1981; 246: 2073-2074.

191. Freemantle N, Cleland J, Young P, et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318:

1730-1737.

192. Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial

infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation 1991; 83: 422-437.

193. Konishi M, Haraguchi G, Yoshikawa S, et al. Additive effects of β-blockers on renin-angiotensin system inhibitors for patients after acute myocardial

infarction treated with primary coronary revascularization. Circ J 2011; 75: 1982-1991.

194. Kernis SJ, Harjai KJ, Stone GW, et al. Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary

angioplasty? J Am Coll Cardiol 2004; 43: 1773-1779.

195. Halkin A, Grines CL, Cox DA, et al. Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical

reperfusion therapy for acute myocardial infarction. J Am Coll Cardiol 2004; 43: 1780-1787.

196. Hawkins NM, MacDonald MR, Petrie MC, et al. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease:

a randomized controlled trial. Eur J Heart Fail 2009; 11: 684-690.

197. Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary

disease: a randomized crossover trial. J Am Coll Cardiol 2010; 55: 1780-1787.

198. 循環器病の診断と治療に関するガイドライン. 大動脈瘤・大動脈解離診療ガイドライン（2011年改訂版）．http://www.j-circ.or.jp/guideline/pdf/JCS2011

_takamoto_h.pdf（2012年8月閲覧）

199. Alfonso F. Spontaneous coronary artery dissection: new insights from the tip of the iceberg? Circulation 2012; 126: 667-670.

200. Tweet MS, Hayes SN, Pitta SR, et al. Clinical features, management, and prognosis of spontaneous coronary artery dissection. Circulation 2012; 126:

579-588.

文献